{"id":62431,"date":"2026-01-02T10:05:56","date_gmt":"2026-01-02T09:05:56","guid":{"rendered":"https:\/\/pharma-trend.com\/en\/frederic-prince-to-succeed-christian-loss-effective-january-1st-2026\/"},"modified":"2026-01-02T10:05:56","modified_gmt":"2026-01-02T09:05:56","slug":"frederic-prince-to-succeed-christian-loss-effective-january-1st-2026","status":"publish","type":"post","link":"https:\/\/pharma-trend.com\/en\/frederic-prince-to-succeed-christian-loss-effective-january-1st-2026\/","title":{"rendered":"Fr\u00e9d\u00e9ric Prince to Succeed Christian Loss, Effective January 1st, 2026"},"content":{"rendered":"
\n

RAPPERSWIL, Switzerland–(BUSINESS WIRE)–Dr. Christian Loss, Chief Executive Officer (CEO) of Neovii Pharmaceuticals AG, will take a well-deserved retirement after his distinguished career at Neovii. As of January, he is succeeded by Fr\u00e9d\u00e9ric Prince PhD, who most recently served as Head of Strategy and Chief of Staff ad interim to the Head of Oncology in Roche’s Pharma Research and Early Development (pRED).<\/p>\n

\nPrior to this, Fr\u00e9d\u00e9ric Prince acted as Project Team Leader in the research and early development department, heading different programs from Immunoncology. Previously, Dr. Prince served in significant leadership roles at biotechnology company bluebird bio, later renamed to Genetix Biotherapeutics. As Vice President and Global Program Lead he headed the eli-cel gene therapy program and as General manager for France he oversaw bluebird bio\u2019s operations in France. Before working in gene therapy, he spent over a decade in leadership roles with increasing responsibilities at Novartis Oncology across the U.S., Switzerland, Italy and France.<\/p>\n

\nThroughout his career, Fr\u00e9d\u00e9ric Prince has acquired extensive experience in both research & development as well as in commercial functions. He earned his PhD in Molecular Genetics and a Master\u2019s Degree in Cell Biology from the Biozentrum of the University of Basel. The Board of Directors extends a warm welcome to Dr. Prince and is confident that he will drive Neovii\u2019s continued growth and development.<\/p>\n

\nAt the same time, the Board would like to express its heartfelt thanks to Dr. Christian Loss for his decades of dedicated service, his successful leadership and invaluable contributions to the development of Neovii Pharmaceuticals. He will continue to be closely connected to the company as a member of our Board of Directors.<\/p>\n

\nwww.neovii.com<\/a><\/p>\n

Contacts<\/b> <\/p>\n

\nContact of Dynamics Group
\n
Utoquai 43 | CH-8008 Z\u00fcrich
\n
contact@dynamicsgroup.ch<\/a><\/p>\n<\/div>\n","protected":false},"excerpt":{"rendered":"

RAPPERSWIL, Switzerland–(BUSINESS WIRE)–Dr. Christian Loss, Chief Executive Officer (CEO) of Neovii Pharmaceuticals AG, will take a well-deserved retirement after his distinguished career at Neovii. As of January, he is succeeded by Fr\u00e9d\u00e9ric Prince PhD, who most recently served as Head of Strategy and Chief of Staff ad interim to the Head of Oncology in Roche’s … [Read more…]<\/a><\/span><\/p>\n","protected":false},"author":4,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[13],"tags":[],"class_list":{"0":"entry","1":"post","2":"publish","3":"author-business","4":"post-62431","6":"format-standard","7":"category-industry"},"yoast_head":"\nFr\u00e9d\u00e9ric Prince to Succeed Christian Loss, Effective January 1st, 2026 - Pharma Trend<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/pharma-trend.com\/en\/frederic-prince-to-succeed-christian-loss-effective-january-1st-2026\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Fr\u00e9d\u00e9ric Prince to Succeed Christian Loss, Effective January 1st, 2026 - Pharma Trend\" \/>\n<meta property=\"og:description\" content=\"RAPPERSWIL, Switzerland–(BUSINESS WIRE)–Dr. Christian Loss, Chief Executive Officer (CEO) of Neovii Pharmaceuticals AG, will take a well-deserved retirement after his distinguished career at Neovii. As of January, he is succeeded by Fr\u00e9d\u00e9ric Prince PhD, who most recently served as Head of Strategy and Chief of Staff ad interim to the Head of Oncology in Roche’s ... [Read more...]\" \/>\n<meta property=\"og:url\" content=\"https:\/\/pharma-trend.com\/en\/frederic-prince-to-succeed-christian-loss-effective-january-1st-2026\/\" \/>\n<meta property=\"og:site_name\" content=\"Pharma Trend\" \/>\n<meta property=\"article:published_time\" content=\"2026-01-02T09:05:56+00:00\" \/>\n<meta name=\"author\" content=\"Business Wire\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Business Wire\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"1 minute\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/frederic-prince-to-succeed-christian-loss-effective-january-1st-2026\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/frederic-prince-to-succeed-christian-loss-effective-january-1st-2026\\\/\"},\"author\":{\"name\":\"Business Wire\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#\\\/schema\\\/person\\\/02d41342c7a74fa7f0032bb35ef0bb24\"},\"headline\":\"Fr\u00e9d\u00e9ric Prince to Succeed Christian Loss, Effective January 1st, 2026\",\"datePublished\":\"2026-01-02T09:05:56+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/frederic-prince-to-succeed-christian-loss-effective-january-1st-2026\\\/\"},\"wordCount\":311,\"publisher\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#organization\"},\"articleSection\":[\"Industry\"],\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/frederic-prince-to-succeed-christian-loss-effective-january-1st-2026\\\/\",\"url\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/frederic-prince-to-succeed-christian-loss-effective-january-1st-2026\\\/\",\"name\":\"Fr\u00e9d\u00e9ric Prince to Succeed Christian Loss, Effective January 1st, 2026 - Pharma Trend\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#website\"},\"datePublished\":\"2026-01-02T09:05:56+00:00\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/frederic-prince-to-succeed-christian-loss-effective-january-1st-2026\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/pharma-trend.com\\\/en\\\/frederic-prince-to-succeed-christian-loss-effective-january-1st-2026\\\/\"]}]},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/frederic-prince-to-succeed-christian-loss-effective-january-1st-2026\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Startseite\",\"item\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Fr\u00e9d\u00e9ric Prince to Succeed Christian Loss, Effective January 1st, 2026\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#website\",\"url\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/\",\"name\":\"Pharma Trend\",\"description\":\"\",\"publisher\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#organization\",\"name\":\"Pharma Trend\",\"url\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"\",\"contentUrl\":\"\",\"caption\":\"Pharma Trend\"},\"image\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#\\\/schema\\\/logo\\\/image\\\/\"}},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#\\\/schema\\\/person\\\/02d41342c7a74fa7f0032bb35ef0bb24\",\"name\":\"Business Wire\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Fr\u00e9d\u00e9ric Prince to Succeed Christian Loss, Effective January 1st, 2026 - Pharma Trend","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/pharma-trend.com\/en\/frederic-prince-to-succeed-christian-loss-effective-january-1st-2026\/","og_locale":"en_US","og_type":"article","og_title":"Fr\u00e9d\u00e9ric Prince to Succeed Christian Loss, Effective January 1st, 2026 - Pharma Trend","og_description":"RAPPERSWIL, Switzerland–(BUSINESS WIRE)–Dr. Christian Loss, Chief Executive Officer (CEO) of Neovii Pharmaceuticals AG, will take a well-deserved retirement after his distinguished career at Neovii. As of January, he is succeeded by Fr\u00e9d\u00e9ric Prince PhD, who most recently served as Head of Strategy and Chief of Staff ad interim to the Head of Oncology in Roche’s ... [Read more...]","og_url":"https:\/\/pharma-trend.com\/en\/frederic-prince-to-succeed-christian-loss-effective-january-1st-2026\/","og_site_name":"Pharma Trend","article_published_time":"2026-01-02T09:05:56+00:00","author":"Business Wire","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Business Wire","Est. reading time":"1 minute"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/pharma-trend.com\/en\/frederic-prince-to-succeed-christian-loss-effective-january-1st-2026\/#article","isPartOf":{"@id":"https:\/\/pharma-trend.com\/en\/frederic-prince-to-succeed-christian-loss-effective-january-1st-2026\/"},"author":{"name":"Business Wire","@id":"https:\/\/pharma-trend.com\/en\/#\/schema\/person\/02d41342c7a74fa7f0032bb35ef0bb24"},"headline":"Fr\u00e9d\u00e9ric Prince to Succeed Christian Loss, Effective January 1st, 2026","datePublished":"2026-01-02T09:05:56+00:00","mainEntityOfPage":{"@id":"https:\/\/pharma-trend.com\/en\/frederic-prince-to-succeed-christian-loss-effective-january-1st-2026\/"},"wordCount":311,"publisher":{"@id":"https:\/\/pharma-trend.com\/en\/#organization"},"articleSection":["Industry"],"inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/pharma-trend.com\/en\/frederic-prince-to-succeed-christian-loss-effective-january-1st-2026\/","url":"https:\/\/pharma-trend.com\/en\/frederic-prince-to-succeed-christian-loss-effective-january-1st-2026\/","name":"Fr\u00e9d\u00e9ric Prince to Succeed Christian Loss, Effective January 1st, 2026 - Pharma Trend","isPartOf":{"@id":"https:\/\/pharma-trend.com\/en\/#website"},"datePublished":"2026-01-02T09:05:56+00:00","breadcrumb":{"@id":"https:\/\/pharma-trend.com\/en\/frederic-prince-to-succeed-christian-loss-effective-january-1st-2026\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/pharma-trend.com\/en\/frederic-prince-to-succeed-christian-loss-effective-january-1st-2026\/"]}]},{"@type":"BreadcrumbList","@id":"https:\/\/pharma-trend.com\/en\/frederic-prince-to-succeed-christian-loss-effective-january-1st-2026\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Startseite","item":"https:\/\/pharma-trend.com\/en\/"},{"@type":"ListItem","position":2,"name":"Fr\u00e9d\u00e9ric Prince to Succeed Christian Loss, Effective January 1st, 2026"}]},{"@type":"WebSite","@id":"https:\/\/pharma-trend.com\/en\/#website","url":"https:\/\/pharma-trend.com\/en\/","name":"Pharma Trend","description":"","publisher":{"@id":"https:\/\/pharma-trend.com\/en\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/pharma-trend.com\/en\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/pharma-trend.com\/en\/#organization","name":"Pharma Trend","url":"https:\/\/pharma-trend.com\/en\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/pharma-trend.com\/en\/#\/schema\/logo\/image\/","url":"","contentUrl":"","caption":"Pharma Trend"},"image":{"@id":"https:\/\/pharma-trend.com\/en\/#\/schema\/logo\/image\/"}},{"@type":"Person","@id":"https:\/\/pharma-trend.com\/en\/#\/schema\/person\/02d41342c7a74fa7f0032bb35ef0bb24","name":"Business Wire"}]}},"_links":{"self":[{"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/posts\/62431","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/users\/4"}],"replies":[{"embeddable":true,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/comments?post=62431"}],"version-history":[{"count":0,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/posts\/62431\/revisions"}],"wp:attachment":[{"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/media?parent=62431"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/categories?post=62431"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/tags?post=62431"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}